A Phase 1 Open-label Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non-hodgkin
  • Age: Between 18 years - 90 years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Histologically confirmed follicular lymphoma (FL) Grades 1-3a, or Grade 3b or histologically confirmed diffuse large B-cell lymphoma (DLBCL) or trFL or additional CD20-positive NHL histologies (e.g., marginal zone lymphoma (MZL) and marginal zone lymphoma (MCL)) may be allowed with Medical Monitor approval during the Dose-Escalation Phase of the study. 2) Relapsed or refractory to at least 2 prior systemic treatment regimens (must include anti-CD20 based chemo-immunotherapy regimen).

You may not be eligible for this study if the following are true:

  • 1) Known Double/Triple Hit Lymphoma (MYC, and BCL-2 or BCL-6 translocation). 2) Chronic Lymphocytic Leukemia (CLL), or Richters transformation.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.